01—Abstract
Summary
Summary of the 8-K filed July 31, 2025. Cited figures are marked; the original filing is the authoritative source.
Bristol Myers Squibb reported Q2 2025 total revenues of $12.3 billiona, up 1% reported and flat on an ex-FX basis.
The headline story is the mix shift: Growth Portfolio revenue rose 18% (17% ex-FX) to $6.6 billionb, driven by immuno-oncology (Opdivo, Yervoy, Opdualag), Breyanzi, Reblozyl, Camzyos and early Cobenfy sales, while the Legacy Portfolio fell 14% to $5.7 billion as Revlimid, Pomalyst and Sprycel erosion from generics continued. U.S. revenue declined 3% and international grew 10%. Eliquis demand was up, though its U.S. growth was partly offset by Medicare Part D redesign effects.
Profitability was dominated by a one-time $1.5 billionc Acquired IPRD charge tied to the June 2025 BioNTech partnership for the BNT327 bispecific antibody, which reduced EPS by $0.57. GAAP diluted EPS was $0.64 (versus $0.83 a year earlier) and non-GAAP EPS was $1.46 (versus $2.07). Excluding the charge, underlying trends were supported by lower SG&A from the productivity initiative and a sharply lower amortization charge, which fell to $830 million from $2.4 billion as Revlimid intangibles amortized down.
Gross margin compressed on product mix, to 72.5% GAAP and 72.6% non-GAAP. Management raised full-year 2025 total revenue guidance to about $46.5d–$47.5 billion from $45.8–$46.8 billion, citing Growth Portfolio strength, better Legacy sales, and roughly $200 million of FX benefit.
Non-GAAP EPS guidance was lowered to $6.35–$6.65 from $6.70–$7.00, reflecting the $0.57 BioNTech charge and roughly $300 million of higher operating expenses from business development and growth investments. Net debt declined to $35.2 billion from $38.5 billion at year-end 2024, and the company is on track to repay about $10 billion of debt by Q2 2026, with about $6.5 billion achieved.
02—Key points
Key Highlights
- Total Q2 2025 revenues of $12.3B, up 1% (flat ex-FX); Growth Portfolio up 18% to $6.6B, now more than half of revenue, while Legacy Portfolio fell 14% to $5.7B.
- GAAP EPS of $0.64 and non-GAAP EPS of $1.46, both including a $(0.57) per-share hit from the BioNTech Acquired IPRD charge (about $1.5B) tied to the BNT327 co-development deal.
- FY2025 revenue guidance raised to ~$46.5–$47.5B from ~$45.8–$46.8B, including ~$200M of favorable FX and better-than-expected Legacy sales.
- FY2025 non-GAAP EPS guidance lowered to $6.35–$6.65 from $6.70–$7.00, driven by the $0.57 IPRD charge; operating expense guidance raised to ~$16.5B.
- Amortization of acquired intangibles fell 66% to $830M, primarily from lower Revlimid amortization, which supports GAAP earnings comparisons going forward.
- Cost discipline continued: non-GAAP SG&A fell 12% and non-GAAP R&D fell 1%, driven by the strategic productivity initiative.
- Net debt reduced to $35.2B from $38.5B at year-end 2024; company is on track to pay down ~$10B of debt by Q2 2026 and has ~$5B of buyback authorization remaining.
03—Questions
Frequently Asked Questions
Why did BMS's EPS decline so sharply in Q2 2025?
Q2 2025 GAAP EPS was $0.64 versus $0.83 a year earlier, and non-GAAP EPS was $1.46 versus $2.07. The main driver was a $1.5 billion Acquired IPRD charge tied to the June 2025 BioNTech partnership, which reduced EPS by $0.57. Gross margin also compressed (72.6% non-GAAP vs. 75.6%), mainly due to product mix. Lower amortization and cost savings partly offset these pressures.
Is the Growth Portfolio offsetting the decline in Legacy products?
Yes, increasingly so. Growth Portfolio revenue rose 18% to $6.6B and now accounts for over half of total revenue, led by Opdivo, Breyanzi, Reblozyl and Camzyos. Legacy Portfolio revenue fell 14% to $5.7B as Revlimid, Pomalyst and Sprycel faced generic erosion. Total revenue was nearly flat (up 1%), indicating the Growth Portfolio is roughly offsetting Legacy declines, though the Revlimid decline is expected to continue.
Why did revenue guidance go up while EPS guidance went down?
Revenue guidance rose by about $700M, reflecting Growth Portfolio strength, better Legacy sales, and roughly $200M of favorable FX. EPS guidance fell by about $0.35 at the midpoint, mainly because of the $0.57 per-share BioNTech IPRD charge and about $300M of higher operating expenses from recent business development and growth investments. Other income guidance was raised to about $250M, which partly offsets these headwinds.
What is the BioNTech deal and why does it matter for investors?
BMS entered a global co-development and co-commercialization agreement with BioNTech for BNT327, an investigational PD-L1/VEGF bispecific antibody being studied across multiple solid tumors. The upfront accounting treatment as an Acquired IPRD charge reduced Q2 2025 results by about $1.5B. Investors should view this as a near-term earnings hit with long-term pipeline upside, as the asset's clinical success is uncertain and the charge excludes future Acquired IPRD or milestone-related items that may still arise.
How is BMS's balance sheet and capital allocation position?
Net debt declined to $35.2B at June 30, 2025, from $38.5B at December 31, 2024. Total cash and marketable securities were about $13.9B, against roughly $49.2B of total debt. Management remains committed to its dividend, has about $5B of share repurchase authorization remaining, and expects to pay down about $10B of debt by the end of Q2 2026, with roughly $6.5B already completed. The company is also pursuing business development to diversify its portfolio.
04—Continue